| Name | Title | Contact Details |
|---|
Founded in 2014 by experienced industry leaders and scientists from University of California at Santa Barbara (UCSB) and Cornell University, Akoustis` mission is to commercialize and manufacture its patent-pending Bulk ONE™ acoustic wave technology to address the critical frequency-selectivity requirements in today`s mobile smartphones – improving the efficiency and signal quality of Mobile Wireless devices and enabling The Internet of Things. The Bulk Acoustic Wave (BAW) filter market is rapidly expanding, driven by growth in 4G/LTE and the number of filters required per device. Nearly 2 billion mobile phones are manufactured per year, and over half are in the growing segment of high-end smartphones. Because these smartphones need to operate globally, on more than one carrier, and with bands that are becoming ever-closer together, the need for higher-performance filters is upon us to ensure mobile compatibility. 4G/LTE networks are driving the need for higher frequencies, and traditional SAW filters simply cannot provide the necessary coverage and performance, as evidenced by the growing mix of BAW filters in the mobile phone. Akoustis™ addresses this critical mobile-wireless need by using single crystal piezoelectric materials to create a new class of acoustic wave filters – improving performance, lowering cost and driving miniaturization. Akoustis` Bulk ONE™ filters originate from materials which exhibit 30% better acoustic performance when compared to the incumbent thin-film technologies deployed today. Akoustis` business model is capital efficient, which leverages decades of cap-x investments in the semiconductor industry. Founded in 2014, Akoustis™ is located in the piedmont technology corridor between Charlotte and Raleigh.
Freedom Photonics is a Santa Barbara, CA-based company in the Computers and Electronics sector.
INTrinsic Semiconductor Corp. is a Sterling, VA-based company in the Computers and Electronics sector.
Rendition is a Mountain View, CA-based company in the Computers and Electronics sector.
Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.